Michiel Voet: The Price Tag of a Whole Blood Strategy
Michiel Voet, Military Medical Logistics Advisor at LS Innoventa bv, shared a post on LinkedIn:
“The price tag of a Whole blood / Spray Dried Plasma strategy.
In modern operations, firepower gets a lot of attention. It seems sexy.
Tomohawks, Storm Shadows, brand new tanks,… We love to talk about it.
Something we barely talk about, however a strategic asset, is blood. Blood keeps our soldiers alive.
But what is the price tag of blood compared to the sexy assets mentioned above.
Let’s put numbers on something we rarely quantify.
1.Scenario (ballpark model):
- 1,000 soldiers deployed
- 1 medic per 10 soldiers
- 3 Role 1 / CCPs
- 2 forward surgical assets
- 10% WIA/KIA rate over 100 days, Average 8 units per casualty transfused, 35% transfusion rate.
2.To ensure golden hour resuscitation capability, we model a system built on:
- Spray-Dried Plasma (every soldier carries 1)
- Whole Blood stocks on R1/CCP/surgical level
- Blood transfusion kits (Pré screened walking blood bank as an Emergency Option)
- Blood warmers and consumables
- Golden Hour Boxes plus reserve
- Cold-chain blood refrigerators plus reserve
- Drone based emergency blood delivery plus reserve
3.Initial deployment cost: €1,893,990
4.Sustainment per following 100 days: €459,874
Ballpark 1,9M€ to give 1,000 soldiers access to modern damage control resuscitation strategy.
Put differently:
That’s roughly €1900 per soldier, to dramatically reduce preventable deaths from hemorrhage, still the Number 1 cause of potentially survivable battlefield fatalities. €1900 per soldier will make sure more of our guys get home…
In comparrison. A Storm Shadow costs about €1 million, a Tomahawk somewhere between €1,2M and €1,8M, a Challenger 2 tank around €8M.
Surely cost can’t be the limiting factor in implementing a proper DCR blood strategy… Certainly when ‘not having blood’ is a limiting factor in your operations.
Anyone else tried to calculate this?
Stay Critical.”
Stay updated with Hemostasis Today.
-
Nov 17, 2026, 01:27X. Long Zheng: Optimizing Treatment in Immune TTP
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C